Drug Eluting Stent Market Report 2026

Drug Eluting Stent Market Overview

• Drug Eluting Stent market size has reached to $8.26 billion in 2025 • Expected to grow to $11.7 billion in 2030 at a compound annual growth rate (CAGR) of 6.9% • Growth Driver: Impact Of Coronary Heart Disease On Drug-Eluting Stent Market • Market Trend: Innovation In Advanced Drug-Eluting Coronary Stents • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Drug Eluting Stent Market?

A drug-eluting stent (DES) is a medical device used in the treatment of coronary artery disease (CAD). It is a small, mesh-like tube typically made of metal that is inserted into narrowed or blocked coronary arteries during a procedure called percutaneous coronary intervention (PCI) or angioplasty. The main product types of drug eluting stents are polymer-based and polymer-free. Polymer-based drug-eluting stents (DES) are stents coated with a thin polymer layer that contains the drug(s) to be delivered to the arterial wall. The drug types include sirolimus, paclitaxel, zotarolimus, everolimus, biolimus, others with scaffolds such as cobalt-chromium, platinum-chromium, nitinol, biodegradable, and others used in applications such as coronary diseases and peripheral vascular disease by end-users such as hospitals and specialty clinics.

What Is The Drug Eluting Stent Market Growth Forecast?

The drug eluting stent market size is expected to see strong growth in the next few years. It will grow to $11.7 billion in 2030 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to growing aging population, increasing demand for minimally invasive cardiac treatments, rising awareness of advanced stent technologies, expansion of specialty cardiac clinics, increasing healthcare expenditure on cardiovascular care. Major trends in the forecast period include rising adoption of biodegradable polymer stents, growing preference for polymer-free drug-eluting stents, increasing use in complex coronary interventions, shift toward long-term restenosis prevention, rising demand for improved drug release control.

What Is The Driver Of The Drug Eluting Stent Market?

The rising burden of coronary heart disease is expected to propel the growth of the drug-eluting stent market going forward. Coronary heart disease (CHD) is a condition where the coronary arteries become narrowed or blocked due to plaque buildup, potentially leading to severe complications such as a heart attack or chest pain. Coronary heart disease is increasing due to sedentary lifestyles, poor diets, aging populations, and heightened awareness. Drug-eluting stents (DES) benefit coronary heart disease by effectively opening narrowed or blocked coronary arteries and releasing medication that helps prevent re-narrowing (restenosis) of the artery. For instance, in August 2025, according to the National Center for Biotechnology Information, a US-based governmental agency, between 2025 and 2050, cardiovascular disease is projected to rise significantly, with prevalence increasing by 90.0%, crude mortality by 73.4%, and crude DALYs by 54.7%, leading to an estimated 35.6 million cardiovascular deaths in 2050, up from 20.5 million in 2025. The rising burden of coronary heart disease is expected to propel the growth of the drug-eluting stench market.

Key Players In The Global Drug Eluting Stent Market

Major companies operating in the drug eluting stent market are Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, Terumo Corporation, BIOTRONIK SE & Co KG, Biosensors International Group Ltd, MicroPort Scientific Corporation, Lepu Medical Technology Beijing Co Ltd, Meril Life Sciences Pvt Ltd, Sahajanand Medical Technologies Pvt Ltd, Alvimedica Medical Technologies, Balton Sp z oo, Cordis (Cardinal Health) DES Manufacturing, Shandong JW Medical Systems Ltd, Sino Medical Sciences Technology Inc, STENTYS SA, Relisys Medical Devices Ltd, Translumina GmbH, Eurocor GmbH, Elixir Medical Corporation

Global Drug Eluting Stent Market Trends and Insights

Major companies operating in the drug eluting stent market are focusing on developing innovative products, such as low profile, high flexibility stents, to improve deliverability in complex coronary anatomies and enhance patient outcomes. A low-profile, high-flexibility stent refers to a drug eluting stent designed with a reduced crossing profile and enhanced flexibility, allowing it to navigate narrow, tortuous, or calcified coronary arteries more easily while maintaining effective drug delivery to prevent restenosis. For instance, in May 2024, Abbott Laboratories, a U.S.-based global healthcare company, launched the XIENCE Sierra Everolimus Eluting Coronary Stent System in India. The XIENCE Sierra features a novel stent design offering best in class deliverability, with significantly reduced crossing force when compared to competitors. It also includes a thinner balloon and an optimized MULTI LINK structure that enhances flexibility, while its high longitudinal strength ensures scaffold stability and resistance to deformation. Additionally, it offers a wide expansion range, allowing precise treatment even when vessel diameters vary markedly along the lesion—enabling interventional cardiologists to treat complex, calcified, or difficult-to-reach lesions with better precision and safety.

What Are Latest Mergers And Acquisitions In The Drug Eluting Stent Market?

In October 2023, Cordis, a US-based developer and manufacturer of interventional vascular medical devices, acquired MedAlliance for an undisclosed amount. The acquisition aims to advance Cordis' legacy of cardiovascular innovation and expand its product portfolio in the coronary and peripheral vascular markets. M.A. Med Alliance SA is a Switzerland-based medical device manufacturer and distributor specializing in drug-eluting stents.

What Defines the Drug Eluting Stent Market?

The drug eluting stent market consists of revenues earned by entities by providing services such as pre-procedural assessment, procedural intervention, intraoperative monitoring, post-procedural care, and patient education. The market value includes the value of related goods sold by the service provider or included within the service offering. The drug eluting stenting market also includes sales of products including guide wires, angioplasty equipment, intravascular imaging systems, hemostasis devices, and diagnostic tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Drug Eluting Stent Market Report 2026?

The drug eluting stent market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the drug eluting stent industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.